1220165-92-3

Usage

Uses

Used in Pharmaceutical Development:
1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid is used as a potential candidate in the development of pharmaceutical drugs for the treatment of certain diseases or conditions. Its unique chemical structure, including the fluorophenyl group and carboxylic acid functional group, may offer specific advantages in drug design and targeting.
Further research and studies are required to fully understand the potential uses and properties of this chemical compound, as its applications in the pharmaceutical industry are still under investigation.

Upstream product

• 1220165-87-6 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid ethyl ester 
• 823-85-8 4-fluorophenyhydrazine hydrochloride 
• 201230-82-2 carbon monoxide 
• 1220165-54-7 4‐bromo‐1‐(4‐fluorophenyl)‐1H‐pyrazolo[3,4‐c]pyridine 
• 371-14-2 4-fluorophenylhydrazine 

Downstream Products

• 1220025-97-7 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid 2-methanesulfonyl-benzylamide 
• 1220166-58-4 {[1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carbonyl]-amino}-acetic acid methyl ester 
• 1220026-26-5 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid (2-methanesulfonyl-pyridin-4-ylmethyl)-amide 
• 1220170-01-3 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid [(S)-1(1H-pyrazol-3-yl)-propyl]-amide 
• 1220171-17-4 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid [(S)-1-(2-methanesulfonyl-pyridin-4-yl)-propyl]-amide 
• 1220123-50-1 (2S,3R)-2-(2-{[1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carbonyl]-amino}-butyrylamino)-3-trityloxy-butyric acid methyl ester 
• 1220123-55-6 (R)-2-(2-{[1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carbonyl]-amino}-butyrylamino)-3-tritylsulfanyl-propionic acid methyl ester 
• 1220126-83-9 2-carbamoyl-4-((S)-1-{[1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carbonyl]-amino}-propyl)-piperidine-1-carboxylic acid benzyl ester 
• 1220168-22-8 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid [(R)-1-(2-bromo-pyridin-4-yl)-2-methoxy-ethyl]-amide 
• 1220171-23-2 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid [(S)-1-(2-methanesulfonyl-pyridin-4-yl)-ethyl]-amide 
• 1220026-14-1 C₂₅H₂₅FN₆O₃S 
• 1295298-15-5 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid [1-(3-bromophenyl)cyclopropyl]amide 
• 1295298-14-4 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid (1-1,3,4-thiadiazol-2-yl-cyclopropyl)amide 
• 1295298-36-0 1-(4-fluorophenyl)-1H-pyrazolo[3,4-c]pyridine-4-carboxylic acid [1-(3-trifluoromethyl-phenyl)cyclopropyl]amide 

Relevant academic research and scientific papers

Identification of novel azaindazole CCR1 antagonist clinical candidates

Exploring various cyclization strategies, using a submicromolar pyrazole HTS screening hit 6 as a starting point, a novel indazole based CCR1 antagonist core was discovered. This report presents the design and SAR of CCR1 indazole and azaindazole antagonists leading to the identification of three development compounds, including 19e that was advanced to early clinical trials.

INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS

Diclosed are CCRl receptor antagonists of the formula (I), wherein X is nitrogen or, C-R2; Ar1 is carbocycle, heteroaryl or heterocyclyl each optionally substituted by one to three Ra; Ar2 is carbocycle, heteroaryl or heterocyclyl, each optionally substituted by one to three Rb; Cyclic G is carbocycle, or heterocyclyl each optionally substituted by one to two R8; R1 is hydrogen, C1-6 alkyl or C 1-6 alkoxyC1-6 alkyl. Also disclosed are compositions, methods of making and using compounds of the formula (I).

AZAINDAZOLE AMIDE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS

Disclosed are CCR1 inhibitor compounds of the formula (I): which are useful in the treatment of autoimmune and other diseases. Also disclosed a pharmaceutical compositions containing the same, and methods of making and using same.

AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.